Analyst upgrades typically have a positive impact on a company's stock price as they indicate increased confidence in the company's performance. In this case, B. Riley Securities' upgrade of Novavax from Neutral to Buy, along with a price target of $15, suggests they believe the stock is undervalued and has potential for growth. This is likely to attract investors and drive up the stock price in the short term.